Help | RSS Feed



TG Therapeutics, Inc. (NASD:TGTX) Seasonal Chart

Seasonal Chart Analysis

Analysis of the TG Therapeutics, Inc. (NASD:TGTX) seasonal charts above shows that a Buy Date of December 29 and a Sell Date of April 18 has resulted in a geometric average return of 54.38% above the benchmark rate of the S&P 500 Total Return Index over the past 20 years. This seasonal timeframe has shown positive results compared to the benchmark in 17 of those periods. This is a very good rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 20 years by an average of 91.28% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

TG Therapeutics Inc is a biopharmaceutical company. It is engaged in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company is developing two therapies targeting hematologic malignancies. TG-1101 (ublituximab) is a novel, glycoengineered monoclonal antibody that targets a unique epitope on the CD20 antigen found on mature B-lymphocytes. It is also developing TGR-1202 (umbralisib), an orally available PI3K delta inhibitor.

To download TGTX seasonal chart data, please log in or Subscribe.

 

Stocks mentioned in this post:

    Search Seasonal Charts by Symbol, Company, or Term

   Symbols by Letter: A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Y | Z


Sponsored By...
Seasonal Advantage Portfolio by CastleMoore